Behind the Guidelines: Insights into the Standard of Care in Oncology 2024 (NCCN Guidelines® Insights 2024)
Each month, the NCCN Guidelines® Insights will be published in JNCCN – Journal of the National Comprehensive Cancer Network.
The goal of this project is to ensure that members of the interprofessional oncology care team, including physicians, nurses, pharmacists and other relevant health care professionals, have the knowledge and skills necessary to understand how and why important decisions are made in the development of NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), and apply this information to clinical decision pathways in oncology.
This series of journal articles is designed to meet the educational needs of oncologists, nurses, pharmacists, and other health care professionals who treat patients with cancer.
Following this activity series, participants should be able to:
- Integrate into professional practice the updates to NCCN Guidelines.
- Describe the rationale behind the decision-making process for developing the NCCN Guidelines.
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
Full disclosure of faculty relationships will be made prior to the activity.
This program has been approved for AMA PRA Category 1 Credit™ for physicians and will award contact hours for nurses, pharmacists, and other health care professionals. Complete accreditation information is provided before each individual educational activity.